A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants with Severe COVID-19 (GS-US-540-5773)
Study Type/Phase: Phase 3
Status: Not Recruiting
The purpose of this study is to evaluate the safety and effectiveness of an investigational drug called Remdesivir (RDV) for COVID-19. There are no approved medications to treat COVID-19, a disease caused by a virus called SARS-CoV-2 that was identified in late 2019. Some people who become sick with COVID-19 develop a very serious disease. Prior testing of RDV has shown antiviral activity against SARS-CoV-2, and has been shown to be safe and tolerable in humans who received this drug in prior studies. Participants with severe COVID-19 symptoms will receive RDV for either 5 days or 10 days while they are at the hospital.
Speak with your doctor to determine whether you meet the following criteria for participation in this study.
|Inclusion Criteria||Exclusion Criteria|
Daniel Shin, MD
Gilead Sciences, Inc.
Kara Turner, Clinical Research Coordinator
Taft Center for Clinical Research
For more information about this clinical trial, including trial status, eligibility and full trial listing, visit www.clinicaltrials.gov.